SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Richard Mazzarella who wrote (1051)12/12/1996 6:49:00 PM
From: Michael Yang   of 4342
 
I think you bought up a very good point. The cocktail may or may not be cheaper than AZT or protease inhibitors or AndroVir alone.
But, who is doing the trial? Way back I remember that Paracelsian had
this in plan, though I never saw any news release in this regard.
Also, a cocktail of drugs might not be tailored to each person's condition because the decrease of the viral load for 37% still means that the each person, with his/her own viral load, may be taking the maximal tolerated amount anyway. So at the end the cocktail may be
more expensive, although it presumably cures better.

Michael
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News